Summary Minutes of the Oncologic Drugs Advisory Committee Meeting

September 19, 2017

Location: FDA White Oak Campus, Building 31 Conference Center, The Great Room (Rm. 1503), Silver Spring, Maryland

Topic: On May 8-9, 2017, the committee discussed supplemental new drug application (sNDA) 021938/033 SUTENT (sunitinib malate) oral capsules, submitted by C.P. Pharmaceuticals International C.V., represented by Pfizer, Inc. (authorized U.S. agent). The proposed indication (use) for this product is for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.

These summary minutes for the September 19, 2017 meeting of the Oncologic Drugs Advisory Committee of the Food and Drug Administration were approved on __10/15/17______.

I certify that I attended the September 19, 2017 meeting of the Oncologic Drugs Advisory Committee and that these minutes accurately reflect what transpired.

/s/ Cindy Chee, PharmD
Acting Designated Federal Officer
Oncologic Drugs Advisory Committee (ODAC)

/s/ Thomas Uldrick, MD, MS
Acting Chairperson, ODAC
Summary Minutes of the Oncologic Drugs Advisory Committee Meeting
September 19, 2017

The following is a final report of the Oncologic Drugs Advisory Committee (ODAC) meeting held on September 19, 2017. A verbatim transcript will be available in approximately six weeks, sent to the Office of Hematology and Oncology and posted on the FDA website at:

https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm547155.htm

All external requests for the meeting transcript should be submitted to the CDER Freedom of Information Office.

The Oncologic Drugs Advisory Committee (ODAC) of the Food and Drug Administration, Center for Drug Evaluation and Research met on September 19, 2017 at the FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, Maryland. Prior to the meeting, members and temporary voting members were provided copies of the briefing materials from the FDA, and C.P. Pharmaceuticals International C.V., represented by Pfizer, Inc. The meeting was called to order by Thomas Uldrick, MD, MS (Acting Chairperson). The conflict of interest statement was read into the record by Cindy Chee, PharmD (Acting Designated Federal Officer). There were approximately 200 people in attendance. There were a total of three Open Public Hearing (OPH) speakers.

Issue: The committee discussed supplemental new drug application (sNDA) 021938/033 SUTENT (sunitinib malate) oral capsules, submitted by C.P. Pharmaceuticals International C.V., represented by Pfizer, Inc. (authorized U.S. agent). The proposed indication (use) for this product is for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.

Attendance:

ODAC Members Present (Voting): Harold J. Burstein, MD, PhD; Susan Halabi, PhD; Philip C. Hoffman, MD; Grzegorz S. Nowakowski, MD; Courtney J. Preusse, MA (Consumer Representative); Alice T. Shaw, MD, PhD; Thomas S. Uldrick, MD, MS (Acting Chairperson)

ODAC Member Not Present (Voting): Heidi D. Klepin, MD, MS; Vassiliki A. Papadimitrakopoulou, MD; Alberto S. Pappo, MD; Gregory J. Riely, MD, PhD; Brian I. Rini, MD, FACP; Bruce J. Roth, MD;

ODAC Members Present (Non-Voting): Phuong Khanh (P.K.) Morrow, MD, FACP

Temporary Members (Voting): Ronald M. Bukowski, MD; Richard D. Lumley, MS, EdD (Patient Representative); Lance C. Pagliaro, MD; Bruce Redman, DO; Ramaprasad Srinivasan, MD, PhD

FDA Participants (Non-Voting): Sundeep Agrawal, MD; Julia Beaver, MD; Laura Fernandes, PhD; V. Ellen Maher, MD; Richard Pazdur, MD; James Xu, MD

Acting Designated Federal Officer (Non-Voting): Cindy Chee, PharmD

Open Public Hearing Speakers: Michael Lawing; Dena Battle; Robert Phillips
The Agenda proceeded as follows:

Call to Order and Introduction of Committee

Thomas Uldrick, MD, MS
Acting Chairperson, ODAC

Conflict of Interest Statement

Cindy Chee, PharmD
Acting Designated Federal Officer, ODAC

Opening Remarks

Julia Beaver, MD
Acting Division Director
Division of Oncology Products 1 (DOP1)
Office of Hematology & Oncology Products (OHOP)
Office of New Drugs (OND), CDER, FDA

APPLICANT PRESENTATIONS

C.P. Pharmaceuticals International C.V., represented by Pfizer, Inc.

Introduction

Sriram Krishnaswami, PhD
Asset Team Leader
Global Product Development
Pfizer Inc.

Non-Metastatic RCC: Unmet Medical Need

Allan Pantuck, MD
Professor of Urology
UCLA Medical Center

Rationale for Adjuvant Treatment and Efficacy

Daniel George, MD
Professor of Medicine and Surgery
Duke University Medical Center

Safety and Quality of Life

Liza DeAnnuntis, MD
Safety Risk Lead/Pharmacovigilance
Worldwide Safety and Regulatory
Pfizer Inc.

FDA PRESENTATIONS

Sutent - Adjuvant Treatment of Renal Cell Carcinoma

James Xu, MD
Clinical Reviewer
DOP1, OHOP, OND, CDER, FDA

Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Cedar-Sinai Medical Center
Clarifying Questions to the Presenters

**BREAK**

**OPEN PUBLIC HEARING**

Questions to the Committee/Committee Discussion

**ADJOURNMENT**

*Question to the Committee:*

S-TRAC randomized patients at high risk of recurrent renal cell carcinoma following nephrectomy to 1 year of Sutent or placebo. Sutent was administered as 50mg orally 4 weeks on and 2 weeks off and could be reduced to 37.5mg. Patients were followed for disease-free survival with scans every 12 weeks for 3 years and then every 6 months for the duration of follow up. Scans were reviewed by the Investigator and by an Independent Radiology Review Committee. Patients were also followed for overall survival. The results of the primary analysis, disease-free survival as determined by the Independent Radiology Review Committee, are shown below.

<table>
<thead>
<tr>
<th></th>
<th>Sutent N = 309</th>
<th>Placebo N = 306</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events</td>
<td>113 (37%)</td>
<td>144 (47%)</td>
</tr>
<tr>
<td>Median Disease-free Survival (95% CI)</td>
<td>6.8 years (5.8, NR)</td>
<td>5.6 years (3.8, 6.6)</td>
</tr>
<tr>
<td>Hazard Ratio (95% CI), p-value</td>
<td>0.76 (0.59, 0.97), p = 0.03</td>
<td></td>
</tr>
</tbody>
</table>

Data Cutoff: 4-2016

The safety profile of Sutent in the adjuvant setting is generally similar to that in patients with metastatic renal cell carcinoma. Adverse events during the treatment period resulted in permanent discontinuation in 28% of patients on Sutent and 5% on placebo. Dose interruptions or delays were required in 46% and dose reductions in 35% of patients on Sutent. Grade 3-4 adverse events occurred in 60% and 15% on the Sutent and placebo arms, respectively.

There have been 21% and 24% deaths on the Sutent and placebo arms, respectively. As of January 2017, the estimated hazard ratio for overall survival is 0.92 (95% CI: 0.66, 1.28). A final analysis is expected in 2019.
1. **VOTE:** Is the benefit-risk profile of Sutent acceptable for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma following nephrectomy?

   YES: 6  NO: 6  ABSTAIN: 0

**Committee Discussion:** The committee was split on whether the benefit-risk profile of Sutent is acceptable for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma following nephrectomy. The panel members who voted “Yes” commented that the side effect profile of Sutent is something that can be discussed between the patient and physician and is thus, manageable. In addition, it was commented that S-TRAC was a large, well conducted study that showed benefit in disease-free survival (DFS) in a specific high risk patient population and that the study addressed an area of unmet need. The members who voted “No” commented that while the study was well designed, an improvement in overall survival has not been seen and there is substantial toxicity with one year of adjuvant Sutent. Please see the transcript for details of the committee discussion.

The meeting on September 19, 2017 was adjourned at approximately 12:04 p.m.